leisure time -WSS

leisure time

author：hotspot 2025-09-03 11:58:12 - browse：9952

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Digital health funding stays low as a new reality sets in

focus

hotspot

WSS

The debate over Covid

'The boss' wants server deleted: New allegations emerge in Trump indictment

Antibody drugs appear effective. Now can we make enough of them?

Biden to sign 'historic' executive order on how US military handles sexual assault cases

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

Inflation cooled significantly in June, bringing price hikes close to normal levels

focus

leisure time

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Tornado touches down near Chicago's O'Hare airport amid extreme weather nationwide

Virginia high school admissions case could be legal follow

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

At least 13 dead in Texas as scorching temps continue

‘We were in the air.’ Mississippi family recounts surviving tornado that tore mobile home apart

Activists slam private health insurers over coverage restrictions

'Hero' Louisville officer shot in head at mass shooting discharged over 3 months later

Wildfire smoke exposes gaps in outdoor worker protections

Inflation cooled significantly in June, bringing price hikes close to normal levels

entertainment

China sends large group of warplanes, navy ships towards Taiwan in forceful display

EU fines Illumina $475 million over Grail acquisition

EU fines Illumina $475 million over Grail acquisition

Britney Spears to release memoir, 'The Woman In Me,' later this year

After half a century, Israel moves to evict squatter from his cave home on the beach

Will biotech layoffs continue through 2023?

explore

focus

hotspot

knowledge